Erkes et al. revealed that a BRAF-MEK inhibitor induces pyroptosis in melanoma cells through the cleavage of GSDME, increased intratumoural T-cell infiltration and immune responses, the release of proinflammatory factors and therapeutic effects [131]. This evidence concerns the gene MAP2K7 and melanoma.